Investment Thesis
West Pharmaceutical demonstrates solid fundamentals with strong profitability metrics, excellent liquidity position, and robust cash generation capabilities. Revenue growth of 6.3% coupled with stable net margins of 16.1% and a 15.3% free cash flow margin indicates quality earnings. The company's fortress balance sheet with minimal leverage (0.06x debt/equity) and exceptional interest coverage of 38.7x provides significant financial flexibility.
WST Strengths
- Exceptional liquidity metrics (3.02x current ratio, 2.34x quick ratio) with substantial cash reserves of $791.3M
- Strong profitability with operating margin of 19.0% and net margin of 16.1% demonstrating operational efficiency
- Excellent free cash flow generation of $468.9M with 15.3% FCF margin relative to revenue, indicating high-quality earnings
- Conservative capital structure with 0.06x debt/equity ratio and 38.7x interest coverage, providing financial stability
- Solid ROE of 15.5% and ROA of 11.6% showing effective deployment of capital
- Moderate revenue growth of 6.3% YoY in medical device sector with consistent earnings
WST Risks
- Modest revenue growth of 6.3% YoY suggests limited near-term expansion momentum in a mature medical device market
- Net income growth of only 0.2% YoY indicates potential margin pressures or demand challenges despite revenue expansion
- High capital intensity with CapEx of $285.9M (36% of operating cash flow) may limit future free cash flow if revenue growth decelerates
- Exposure to regulatory changes and reimbursement pressures inherent in medical devices sector
- Significant insider activity with 17 Form 4 filings in last 90 days warrants monitoring for potential concerning transactions
Key Metrics to Watch
- Revenue growth trajectory and gross margin trends to assess demand and pricing power
- Free cash flow sustainability and capital expenditure efficiency relative to revenue growth
- Operating leverage as volumes scale, particularly operating margin expansion potential
- Return on invested capital trends and capital allocation efficiency
WST Financial Metrics
WST Profitability Ratios
WST Balance Sheet & Liquidity
WST 5-Year Financial Trend
5-Year Trend Summary: WEST PHARMACEUTICAL SERVICES INC's revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $7.88 reflects profitable operations.
WST Growth Metrics (YoY)
WST Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $746.9M | $89.8M | $1.85 |
| Q2 2025 | $702.1M | $89.8M | $1.51 |
| Q1 2025 | $695.4M | $89.8M | $1.23 |
| Q3 2024 | $746.9M | $111.3M | $1.85 |
| Q2 2024 | $702.1M | $111.3M | $1.51 |
| Q1 2024 | $695.4M | $115.3M | $1.55 |
| Q3 2023 | $686.9M | $120.6M | $1.59 |
| Q2 2023 | $753.8M | $140.0M | $2.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
WST Capital Allocation
WST SEC Filings
Access official SEC EDGAR filings for WEST PHARMACEUTICAL SERVICES INC (CIK: 0000105770)